Durable pulmonary vein isolation with diffuse posterior left atrial ablation using low-flow, median power, short-duration strategy.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
08 2022
Historique:
revised: 29 03 2022
received: 09 02 2022
accepted: 13 04 2022
pubmed: 23 5 2022
medline: 24 8 2022
entrez: 22 5 2022
Statut: ppublish

Résumé

To target posterior wall isolation (PWI) in atrial fibrillation (AF) ablation, diffuse ablation theoretically confers a lower risk of conduction recovery compared to box set. We sought to assess the safety and efficacy of diffuse PWI with low-flow, medium-power, and short-duration (LF-MPSD) ablation, and evaluate the durability of pulmonary vein isolation (PVI) and PWI among patients undergoing repeat ablations. We retrospectively studied patients undergoing LF-MPSD ablation for AF (PVI + diffuse PWI) between August 2017 and December 2019. Clinical characteristics were collected. Kaplan-Meier survival analysis was performed to study AF/atrial flutter (AFL) recurrence. Ablation data were analyzed in patients who underwent a repeat AF/AFL ablation. Of the 463 patients undergoing LF-MPSD AF ablation (PVI alone, or PVI + diffuse PWI), 137 patients had PVI + diffuse PWI. Acute PWI with complete electrocardiogram elimination was achieved in 134 (97.8%) patients. Among the 126 patients with consistent follow-up, 38 (30.2%) patients had AF/AFL recurrence during a median duration of 14 months. Eighteen patients underwent a repeat AF/AFL ablation after PVI + diffuse PWI, and 16 (88.9%) patients had durable PVI, in contrast to 10 of 45 (23.9%) patients who had redo ablation after LF-MPSD PVI alone. Seven patients (38.9%) had durable PWI, while 11 patients had partial electrical recovery at the posterior wall. The median percentage of area without electrical activity at the posterior wall was 70.7%. Conduction block across the posterior wall was maintained in 16 (88.9%) patients. There was a high rate of PVI durability in patients undergoing diffuse PWI and PVI. Partial posterior wall electrical recovery was common but conduction block across the posterior wall was maintained in most patients.

Identifiants

pubmed: 35598280
doi: 10.1111/jce.15550
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1655-1664

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;(9):632-696.
Clarnette JA, Brooks AG, Mahajan R, et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2018;20:366-376.
Abdulla R, Blew GA, Holterman MJ. Cardiovascular embryology. Pediatr Cardiol. 2004;25:191-200.
Santangeli P, Marchlinski FE. Techniques for the provocation, localization, and ablation of non-pulmonary vein triggers for atrial fibrillation. Heart Rhythm. 2017;14:1087-1096.
Thiyagarajah A, Kadhim K, Lau DH, et al. Feasibility, safety, and efficacy of posterior wall isolation during atrial fibrillation ablation: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2019;12:e007005.
Kumar S, Romero J, Stevenson WG, et al. Impact of lowering irrigation flow rate on atrial lesion formation in thin atrial tissue: preliminary observations from experimental and clinical studies. JACC Clin Electrophysiol. 2017;3:1114-1125.
Yavin HD, Leshem E, Shapira-Daniels A, et al. Impact of high-power short-duration radiofrequency ablation on long-term lesion durability for atrial fibrillation ablation. JACC Clin Electrophysiol. 2020;6:973-985.
Chinitz JS, Kapur S, Barbhaiya C, et al. Sites with small impedance decrease during catheter ablation for atrial fibrillation are associated with recovery of pulmonary vein conduction. J Cardiovasc Electrophysiol. 2016;27:1390-1398.
Daimee UA, Akhtar T, Boyle TA, et al. Repeat catheter ablation for recurrent atrial fibrillation: electrophysiologic findings and clinical outcomes. J Cardiovasc Electrophysiol. 2021;32:628-638.
McLellan AJA, Prabhu S, Voskoboinik A, et al. Isolation of the posterior left atrium for patients with persistent atrial fibrillation: routine adenosine challenge for dormant posterior left atrial conduction improves long-term outcome. Europace. 2017;19:1958-1966.
Winkle RA, Mead RH, Engel G, et al. High-power, short-duration atrial fibrillation ablations using contact force sensing catheters: outcomes and predictors of success including posterior wall isolation. Heart Rhythm. 2020;17:1223-1231.
Markman TM, Hyman MC, Kumareswaran R, et al. Durability of posterior wall isolation after catheter ablation among patients with recurrent atrial fibrillation. Heart Rhythm. 2020;17:1740-1744.
Kumagai K, Toyama H. High-power, short-duration ablation during Box isolation for atrial fibrillation. J Arrhythm. 2020;36:899-904.
Jiang R, Buch E, Gima J, et al. Feasibility of percutaneous epicardial mapping and ablation for refractory atrial fibrillation: insights into substrate and lesion transmurality. Heart Rhythm. 2019;16:1151-1159.
Higuchi S, Sohara H, Nakamura Y, et al. Is it necessary to achieve a complete box isolation in the case of frequent esophageal temperature rises? Feasibility of shifting to a partial box isolation strategy for patients with non-paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2016;27:897-904.
O'Neill L, Hensey M, Nolan W, Keane D. Clinical outcome when left atrial posterior wall box isolation is included as a catheter ablation strategy in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2015;44:63-70.
Tamborero D, Mont L, Berruezo A, et al. Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study. Circ Arrhythm Electrophysiol. 2009;2:35-40.
Beinart R, Abbara S, Blum A, et al. Left atrial wall thickness variability measured by CT scans in patients undergoing pulmonary vein isolation. J Cardiovasc Electrophysiol. 2011;22:1232-1236.
Kowalski M, Grimes MM, Perez FJ, et al. Histopathologic characterization of chronic radiofrequency ablation lesions for pulmonary vein isolation. J Am Coll Cardiol. 2012;59:930-938.
Bhaskaran A, Chik W, Pouliopoulos J, et al. Five seconds of 50-60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. Europace. 2017;19:874-880.

Auteurs

Dan L Li (DL)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Majd El-Harasis (M)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Jay A Montgomery (JA)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Travis D Richardson (TD)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Arvindh Kanagasundram (A)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Juan Carlos Estrada (JC)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Michael Lean (M)

Biosense-Webster Inc, Irvine, California, USA.

M Benjamin Shoemaker (MB)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Pablo J Saavedra (PJ)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Steven Touchton (S)

Biosense-Webster Inc, Irvine, California, USA.

Bindiya Patel (B)

Biosense-Webster Inc, Irvine, California, USA.

Tarrah Herrmann (T)

Biosense-Webster Inc, Irvine, California, USA.

Roy M John (RM)

Division of Cardiology, Department of Medicine, Stanford University, Stanford, California, USA.

Gregory F Michaud (GF)

Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH